Top 5 Medical Stocks To Own Right Now

tags:BDX,CRM,WRD,RDY,CALM,

North America's legal marijuana market is expected to soar 145%, from $10 billion in 2017 to $24.5 billion by 2021. With such tremendous profit potential, we're bring you the best marijuana stock to buy this year to help you profit from this booming industry.

While there are several marijuana stocks poised to gain from cannabis' gradual legalization, we've found a company that's generating staggering profits from the most robust sector of the current marijuana industry – medical marijuana.

You see, while only a nine U.S. states have legalized marijuana for recreational use, 29 states and the District of Columbia have approved medical marijuana sales and use.

Top 5 Medical Stocks To Own Right Now: Becton, Dickinson and Company(BDX)

Advisors' Opinion:

• [By Logan Wallace]

  Evergreen Capital Management LLC grew its holdings in shares of Becton Dickinson (NYSE:BDX) by 12.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 15,558 shares of the medical instruments supplier’s stock after acquiring an additional 1,768 shares during the quarter. Evergreen Capital Management LLC’s holdings in Becton Dickinson were worth $3,371,000 as of its most recent SEC filing.

• [By John Ballard]

  Shares of Becton Dickinson (NYSE:BDX) gained 10.7% last month, according to data provided by S&P Global Market Intelligence. After falling with the broader market in late 2018 over concerns about the economy, investors breathed a sigh of relief when the company announced positive preliminary results for its first quarter of fiscal 2019. The company's actual fiscal first-quarter earnings report on Feb. 5 was as solid as expected. 

• [By Keith Speights]

  Dividend Yield

  Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88% AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97% Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29% DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77% Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57% Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14% Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22% Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61% Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82% Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64% Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/A

  Data source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.

• [By Motley Fool Transcription]

  Becton Dickinson and Co. (NYSE:BDX)Q1 2019 Earnings Conference CallFeb. 5, 2019, 8:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Brian Feroldi]

  Here's are some of the biggest and best-know publicly traded diabetes companies:

  Company Ticker Market Cap Products  Abbott Laboratories (NYSE: ABT) $126 billion Continuous glucose monitor AstraZeneca (NYSE: AZN) $95 billion Pharmaceuticals Becton, Dickinson (NYSE: BDX) $70 billion Diagnostic and delivery devices DexCom (NASDAQ:DXCM) $12.7  billion Continuous glucose monitor Eli Lilly (NYSE: LLY) $106 billion Insulin and pharmaceuticals Insulet   (NASDAQ:PODD) $6.1 billion Insulin pump Johnson & Johnson (NYSE: JNJ) $375 billion  Glucose monitor and pharmaceuticals Lexicon Pharmaceuticals (NASDAQ: LXRX) $1.2 billion Pharmaceuticals MannKind (NASDAQ: MNKD) $291 million Inhaled insulin Medtronic (NYSE: MDT) $133  billion Insulin pumps and continuous glucose monitor Novo Nordisk (NYSE:NVO) $116 billion Insulin and pharmaceuticals Sanofi (NYSE: SNY) $108 billion Insulin and pharmaceuticals Senseonics Holdings (NYSEMKT: SENS) $834 million Continuous glucose monitor

  DATA SOURCE: YAHOO! FINANCE. MARKET CAP DATA AS OF 9/25/2018. 

Top 5 Medical Stocks To Own Right Now: Salesforce.com Inc(CRM)

Advisors' Opinion:

• [By ]

  China's President Xi Jinping did his part to support the bull market in stocks via a conciliatory trade speech on Monday night, and now embattled Facebook (FB)  founder Mark Zuckerberg has to follow course. By now, seemingly ever pundit and journalist has weighed in how the camera-averse Zuckerberg will perform over the next two days in front of savage lawmakers. So there isn't much new to add until we watch him sit down and do battle. But one gets the sense that lawmakers won't have any clue what to truly ask Zuck in the attempt to send his stock price down the tubes again (because they would secretly love nothing better than to hit Zuck in his digital wallet, naturally). Sure, they may get under his notoriously thin skin, but investors worried about a full-on stock price rout should rest somewhat easy. The Facebooks evolution that is well underway, and which is being accelerated post the Cambridge Analytica debacle, will over time erode the company's highly lucrative business model. You probably won't see any evidence of the derision in the first-quarter results or perhaps even the rest of 2018. It's happening as we speak though, and should be something Zuck reflects in 2019 profit guidance (which should be issued) at some point later this year. In the meantime, enjoy the great theater and tread easily with Facebook's stock off the March mini-rally. Better trades into this spectacle if you haven't put them on already: big data business plays such as Dropbox (DBX) , Salesforce (CRM) , and Action Alerts PLUS holdings Microsoft (MSFT) and Nvidia (NVDA) .   

• [By ]

  Disney (DIS) , Expedia (EXPE) , Turner, Comcast (CMCSA) , GoDaddy (GDDY) , GE (GE) , Capital One (COF) , Netflix (NFLX) (yes, Netflix) Salesforce.com (CRM) and Workday (WDAY) disclosed similar moves in the past. While other business units and large enterprises followed the same path, but chose to keep them private.

• [By Daniel Sparks]

  Cloud-based sales platform Salesforce.com (NYSE:CRM) announced on Monday that it has entered a definitive agreement to acquire the artificial intelligence-powered marketing and analytics platform Datorama. By providing marketing insights for over 3,000 global agencies and brands, including PepsiCo, Trivago, and Unilever, Datorama can help Salesforce build on its strong momentum in its fast-growing marketing and commerce cloud.

• [By Joseph Griffin]

  salesforce.com, inc. (NYSE:CRM) CEO Keith Block sold 2,160 shares of the business’s stock in a transaction on Tuesday, October 9th. The stock was sold at an average price of $148.05, for a total value of $319,788.00. Following the sale, the chief executive officer now owns 23,836 shares of the company’s stock, valued at approximately $3,528,919.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

• [By Daniel Sparks]

  Amid the S&P 500's nearly 5% gain over the past six months, one subsector has done exceptionally well: software-as-a-service (SaaS) stocks, particularly those providing platforms and applications to help businesses. The market seems head over heels for these stocks. Cloud-based customer relationship management company salesforce.com (NYSE:CRM), financial software company Intuit (NASDAQ:INTU), e-commerce platform Shopify (NYSE:SHOP), and payment processor Square (NYSE:SQ) have all soared 30% or more during the last six months alone.

Top 5 Medical Stocks To Own Right Now: WildHorse Resource Development Corporation (WRD)

Advisors' Opinion:

• [By Matthew DiLallo]

  Shares of WildHorse Resource Development Corp. (NYSE:WRD) fell more than 13% by 11 a.m. EDT on Wednesday after the Eagle Ford shale driller posted disappointing second-quarter results.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on WildHorse Resource Development (WRD)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  Wildhorse Resource Development Corp (NYSE:WRD) – Equities research analysts at Capital One Financial lowered their FY2018 earnings per share estimates for Wildhorse Resource Development in a research note issued to investors on Monday, August 20th. Capital One Financial analyst B. Velie now forecasts that the oil and natural gas company will post earnings of $1.59 per share for the year, down from their previous estimate of $1.87. Capital One Financial also issued estimates for Wildhorse Resource Development’s Q4 2018 earnings at $0.39 EPS and FY2019 earnings at $2.07 EPS.

• [By Joseph Griffin]

  Wildhorse Resource Development Corp (NYSE:WRD) shares dropped 5.3% on Monday . The stock traded as low as $18.40 and last traded at $18.66. Approximately 1,428,160 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 1,115,212 shares. The stock had previously closed at $19.71.

Top 5 Medical Stocks To Own Right Now: Dr. Reddy's Laboratories Ltd(RDY)

Advisors' Opinion:

• [By Shane Hupp]

  Dr.Reddy’s Laboratories (NYSE:RDY) was upgraded by analysts at ValuEngine from a sell rating to a hold rating.

  Regenxbio (NASDAQ:RGNX) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.

• [By Keith Speights]

  Investors' biggest worry about Celgene is that it might not have as much time as hoped to replace the revenue that Revlimid generates: Dr. Reddy's Laboratories (NYSE:RDY) is challenging Celgene's patents for Revlimid.

• [By Keith Speights]

  The third reason behind Celgene's low valuation is a potential threat to the biotech's top drug Revlimid. Celgene is fighting a patent challenge over Revlimid from Dr. Reddy's Laboratories (NYSE:RDY). The hematology drug currently generates 63% of Celgene's total revenue. 

• [By Lisa Levin] Companies Reporting Before The Bell Advance Auto Parts, Inc. (NYSE: AAP) is projected to report quarterly earnings at $1.97 per share on revenue of $2.91 billion. Kohl's Corporation (NYSE: KSS) is expected to report quarterly earnings at $0.5 per share on revenue of $3.95 billion. The TJX Companies, Inc. (NYSE: TJX) is projected to report quarterly earnings at $1.02 per share on revenue of $8.47 billion. AutoZone, Inc. (NYSE: AZO) is estimated to report quarterly earnings at $13.01 per share on revenue of $2.72 billion. Dycom Industries, Inc. (NYSE: DY) is projected to report quarterly earnings at $0.7 per share on revenue of $734.86 million. Eaton Vance Corp. (NYSE: EV) is estimated to report quarterly earnings at $0.79 per share on revenue of $425.42 million. Photronics, Inc. (NASDAQ: PLAB) is expected to report quarterly earnings at $0.07 per share on revenue of $124.17 million. Cracker Barrel Old Country Store, Inc. (NASDAQ: CBRL) is estimated to report quarterly earnings at $1.93 per share on revenue of $715.15 million. Radcom Ltd. (NASDAQ: RDCM) is expected to post quarterly earnings at $1.96 per share on revenue of $718.59 million. Clear Channel Outdoor Holdings, Inc. (NYSE: CCO) is projected to report quarterly earnings at $0.04 per share on revenue of $718.96 million. CYREN Ltd. (NASDAQ: CYRN) is estimated to report quarterly loss at $0.08 per share on revenue of $7.72 million. Ferroglobe PLC (NYSE: GSM) is projected to report quarterly earnings at $0.16 per share on revenue of $559.15 million. Dr. Reddy's Laboratories Limited (NYSE: RDY) is estimated to report earnings for its fourth quarter. BioLineRx Ltd. (NASDAQ: BLRX) is expected to report quarterly loss at $0.07 per share. Toll Brothers, Inc. (NYSE: TOL) is estimated to post quarterly earnings at $0.76 per share on revenue of $1.58 billion.

   

Top 5 Medical Stocks To Own Right Now: Cal-Maine Foods, Inc.(CALM)

Advisors' Opinion:

• [By Shane Hupp]

  News headlines about Cal-Maine Foods (NASDAQ:CALM) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cal-Maine Foods earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the basic materials company an impact score of 45.5279430715424 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

• [By Dan Caplinger]

  Monday was generally a good day for the stock market, although major benchmarks showed a considerable amount of variation in how they performed. The Dow Jones Industrial Average and S&P 500 seemed to benefit the most from news that the U.S., Mexico, and Canada had resolved their trade differences and come to a trilateral agreement, but the Nasdaq Composite lagged, and small-cap stocks posted substantial declines. Also hurting the overall market were some disturbing developments regarding some key companies. Infinera (NASDAQ:INFN), Akorn (NASDAQ:AKRX), and Cal-Maine Foods (NASDAQ:CALM) were among the worst performers on the day. Here's why they did so poorly.

• [By Logan Wallace]

  Cal-Maine Foods Inc (NASDAQ:CALM) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $52.15 and last traded at $52.25, with a volume of 5956 shares trading hands. The stock had previously closed at $51.05.

• [By Garrett Baldwin]

  Get an exclusive invitation to meet Tim before everyone else right here.

  Three Stocks to Watch Today: LC, GE, GS General Electric Co. (NYSE: GE) has ousted its CEO John Flannery. Shares are up more than 10% as investors celebrated the news. GE has been mired in a slump, particularly its turbine business. The firm's new CEO is H. Lawrence Culp, Jr., the former CEO of the industrial firm Danaher. Shares of LendingClub Corp. (NYSE: LC) are under pressure after the SEC charged one of the firm's divisions with mishandling client money. This weekend, the firm reached a settlement with regulators on charges that the firm inflated its revenue and made changes to products to make the firm look healthier than it is. As a result, the firm's board of directors forced CEO Renaud Laplanche to resign. Goldman Sachs Group Inc. (NYSE: GS) has replaced CEO Lloyd Blankfein, who has stepped down after more than a decade at the helm at one of Wall Street's most iconic banks. David Solomon – who has previously served as the firm's president and COO – will now bet the new CEO. His tenure begins at a tough time for Goldman as the bank struggles with lower trading desk revenues. Look for earnings reports today from Cal-Maine Foods Inc. (NASDAQ: CALM) and Xcerra Corp. (NASDAQ: XCRA).

  Follow Money Morning on Facebook, Twitter, and LinkedIn.